A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

Inclusion Criteria: * Age 16 years or above at the time of the screening * Ability and willingness to provide written informed consent and to comply with the schedule of protocol requirements * Diagnosis of SLE * Active lupus nephritis Exclusion Criteria: * Currently active retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia * Severe renal impairment * Lack of peripheral venous access * Pregnancy or breast feeding mothers * History of severe allergic or anaphylactic reactions to humanized, chimeric or murine monoclonal antibodies or i.v. immunoglobulin * Known severe chronic pulmonary disease * Evidence of significant uncontrolled concomitant diseases in any organ system not related to SLE, which, in the investigator's opinion, would preclude patient participation * Concomitant condition which has required treatment with systemic corticosteroid (excluding topical or inhaled steroids) prior to screening * Known HIV or chronic active Hepatitis B or chronic active Hepatitis C infection * Known active infection of any kind prior to Day 1 * History of serious recurrent or chronic infection * History of cancer, including solid tumors, hematological malignancies and carcinoma in situ (except basal cell carcinoma of the skin that has been excised and cured). * History of alcohol or drug abuse prior to screening * Major surgery prior to screening, excluding diagnostic surgery * Previous treatmen…